a method of treating egfr cancer targeted to erlotinib or gefitinib resistant or using a pharmaceutically acceptable salt in an individual

• 收藏
• 分享

专利权人:

ARIAD PHARMACEUTICALS; INC.

发明人:

DAVID C. DALGAMO,JUAN J. MIRET,VICTOR M. RIVERA,WILLIAM C. SHAKEPEARE,XIAOTIAN ZHU

申请号：

BR112013008816

公开号：

BR112013008816A2

申请日:

2011.10.14

申请国别(地区):

BR

年份:

2016

代理人:

摘要：

The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/